行情

RDY

RDY

如瑞迪博士
NYSE

实时行情|Nasdaq Last Sale

61.30
-0.48
-0.78%
盘后: 61.44 +0.14 +0.23% 17:40 03/05 EST
开盘
60.99
昨收
61.78
最高
61.53
最低
60.30
成交量
26.35万
成交额
--
52周最高
73.50
52周最低
33.33
市值
101.72亿
市盈率(TTM)
48.47
分时
5日
1月
3月
1年
5年
每日生物技术动向:Novavax疫苗供应协议,Travere的孤儿药名称,Quidel的COVID-19 Boost,Opko
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 19)
Benzinga · 02/19 12:25
雷迪博士开始为印度的俄罗斯Sputnik V COVID-19疫苗启动EUA流程
Benzinga · 02/19 11:26
雷迪博士说Sputnik V疫苗已启动紧急使用授权程序
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) today announced that it has initiated the process with the Drugs Controller General of India (DCGI) for Emergency Use Authorization (EUA) of the well-studied human adenoviral vector-based platform vaccine candidate...
Benzinga · 02/19 10:50
雷迪博士实验室在美国市场推出卡培他滨片USP
Dr. Reddy's Laboratories Ltd. (NYSE: RDY)) today announced the launch of Capecitabine Tablets, USP a therapeutic equivalent generic version of Xeloda (capecitabine) Tablets approved by the U.S. Food and Drug Administration (USFDA).
Benzinga · 02/17 10:23
Allstate,Cirrus Logic,EA,Zillow等星期二下午的分析师电话会议
247WallSt.com · 02/02 17:46
雷迪博士宣布的在科威特终止住院的中度至重度Covid-19病例的研究终止,而在北美继续进行轻度至中度门诊患者的研究
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) and Global Response Aid FZCO (GRA) today announced the termination of Avigan Trial Study conducted in Kuwait focused on moderate to severe COVID patients in a hospital setting.
Benzinga · 01/27 10:42
雷迪博士重申早先的公关说Sputnik V在印度的2期临床试验中达到了安全性的主要终点
Sputnik V meets the primary endpoint of safety in the Phase 2 Clinical Trial in India Dr. Reddy's submitted the phase 2 safety data for DCGI's approval to continue phase 3 clinical trials Dr. Reddy's
Benzinga · 01/11 15:26
雷迪博士实验室的市盈率见解
In the current session, Dr Reddy's Laboratories Inc. (NYSE:RDY) is trading at $72.80, after a 1.39% gain. Over the past month, the stock increased by 6.40%, and in the past year, by 73.88%. With performance like this, long-term shareholders optimistic but ...
Benzinga · 01/11 14:56
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解RDY最新的财务预测,通过RDY每股收益,每股净资产,每股现金流等数据分析如瑞迪博士近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测RDY价格均价为72.50,最高价位74.99,最低价为70.00。
EPS
机构持股
总机构数: 254
机构持股: 2,103.05万
持股比例: 12.67%
总股本: 1.66亿
类型机构数股数
增持
46
73.12万
建仓
38
-33.14万
减持
77
288.34万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
+1.51%
制药与医学研究
+1.63%
高管信息
Chairman/Director
Satish Reddy
Co-Chairman/Managing Director/Director
G. Prasad
Chief Executive Officer
Erez Israeli
Corporate Executive
MARC KIKUCHI
Chief Financial Officer
Parag Agarwal
Corporate Executive
Patrick Aghanian
Corporate Executive
Marc Kikuchi
Corporate Executive
M. Ramana
Chief Human Resource Officer
Archana Bhaskar
Other
Raymond De Vre
Other
Sauri Gudlavalleti
Other
Ganadhish Kamat
Other
Anil Namboodiripad
Other
YUGANDHAR PUVVALA
Other
Yugandhar Puvvala
Other
Deepak Sapra
Other
SANJAY SHARMA
Other
Sanjay Sharma
Secretary
Sandeep Poddar
Non-Executive Independent Director
Bruce Carter
Non-Executive Independent Director
Bharat Doshi
Non-Executive Independent Director
Sridar Iyengar
Non-Executive Independent Director
Prasad Menon
Non-Executive Independent Director
Kalpana Morparia
Non-Executive Independent Director
Allan Oberman
Non-Executive Independent Director
Leo Puri
Non-Executive Independent Director
Shikha Sharma
公告日期
每股分红
除权日期
2020/06/26
每股分红:USD 0.2769603
2020/07/10
--
每股分红:USD 0.262229
2019/07/12
--
每股分红:USD 0.272
2018/07/13
2017/08/04
每股分红:USD 0.294
2017/07/13
2016/08/03
每股分红:USD 0.279
2016/07/14
2015/08/11
每股分红:USD 0.293
2015/07/08
2014/08/08
每股分红:USD 0.272
2014/08/01
--
每股分红:USD 0.283
2014/07/09
2013/08/08
每股分红:USD 0.225
2013/07/10
RDY 简况
Dr. Reddy's Laboratories Limited是一家提供药品的制药公司。该公司有三个业务部门:全球仿制药部门、制药服务和活性成分(PSAI)部门和专有产品部门。全球仿制药部门制造和销售可供患者食用的处方药和非处方药成品,以商标名称(品牌配方)或作为与品牌配方(仿制药)等效疗性的通用成品剂来销售。PSAI部门包括生产和销售活性药物成分和中间体(API)或原料药的业务。专有产品部门从事差异化配方和新化学实体的研究、开发和制造业务。该公司的产品应用于皮肤病学和神经病学治疗领域,通过子公司Promius Pharma, LLC进行营销和销售。

微牛提供Dr.Reddy's Laboratories Ltd (ADR)(NYSE-RDY)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的RDY股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易RDY股票基本功能。